Vertex still has an ongoing diabetes partnership with CRISPR, which gives it a non-exclusive license to the latter’s platform to develop a potential cure for type 1 diabetes.
2023 was a breakthrough year for cell and gene therapies, with seven FDA approvals in the U.S. and one in the European Union, according to the Alliance for Regenerative Medicine. Looking to 2024, the Washington, D.C.–based advocacy organization predicted that the sector could see up to 17 approvals in the U.S. and EU.
Today the company said it expects to return to revenue growth in 2025 when the ongoing decline in its COVID-19 vaccine business would bottom out, and that it would invest to scale up its oncology business thereafter.
Aiolos focuses on therapies for respiratory and inflammatory conditions, and is currently developing ‘AIO-001’, a treatment for asthma which is ready to enter mid-stage clinical trials.
“Pfizer’s position is that we believe that obesity is a place that we have the ability to play and win. So we will have to play,” Bourla told reporters ahead of his presentation at the JPMorgan healthcare conference in San Francisco.
Moderna-backed Metagenomi is a precision genetics medicines company with what it describes as a comprehensive genome editing toolbox consisting of programmable nucleases, base editors, RNA-mediated integration systems and CRISPR-based techniques.
Ambrx is developing therapies that belong to the class of drugs called antibody drug conjugates (ADC), which are described by researchers as “guided missiles” to target cancer cells and minimize damage to healthy tissue.
The U.S. drugmaker has been doubling down on building future revenue streams as its blockbuster immunotherapy, Keytruda, inches closer to losing key patents, opening the doors for competition from biosimilars.
Yesterday’s dual agreements with Umoja continues AbbVie’s dealmaking spree in late 2023, which saw the pharma ink two multibillion-dollar agreements. The first was with ImmunoGen and its deep portfolio of antibody-drug conjugates (ADC), which AbbVie bought for $10.1 billion.
Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.
